Advice
Following a re-submission
betaine anhydrous (Cystadane) is not recommended for use within NHS Scotland as adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR) or cobalamin cofactor metabolism (cbl).
Clinical efficacy data for betaine anhydrous are limited.
The manufacturer did not present a sufficiently robust economic evaluation to gain acceptance by SMC.
Download detailed advice79KB (PDF)
Medicine details
- Medicine name:
- betaine anhydrous oral powder (Cystadane)
- SMC ID:
- 407/07
- Indication:
- Adjunctive treatment of homocystinuria
- Pharmaceutical company
- Orphan Europe (UK) Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 09 March 2009